2016 Snooker China Championship Live Room Higgins vs Allen’s latest match video today_1

2016 Snooker China Championship Live Room Higgins vs Allen’s latest match video today
Evergrande 2016 World Snooker China Championship (Attachment: 2016 World Snooker China Championship Complete Schedule Schedule + 2016 Snooker China Championship Contest Player Matchlist/Signature) will be from November 1st to 5th this yearOfficially started in the Guangzhou Stadium.  Evergrande 2016 World Snooker China Championship semi-finals will adopt a 17-game 9-win system. The first stage will play 8 games first, and the second stage will complete the next 9 games.2016斯诺克中国锦标赛半决赛——希金斯vs艾伦  恒大2016世界斯诺克中国锦标赛约翰-希金斯vs马克-艾伦的比赛时间于北京时间11月4日下午14:30分The first stage will be held and the second stage will be held at 19:30 on the same day.Watch the game live: 2016 World Snooker China Championship match video live room 2016 Snooker China Championship Live

18 A-share pharmaceutical companies release 2019 annual report

18 A-share pharmaceutical companies release 2019 annual report
According to the data provided by Tonghuashun, as of 18:00 on March 20, a total of 18 listed pharmaceutical companies released the 2019 annual report.Among them, at least the most serious is the Asia-Pacific pharmaceutical industry, the expansion of more than 2 billion US dollars, net profit increased by at least 1095.57%; the largest increase was in Wuzhong, Jiangsu, with an annual increase of 131.75%.In 2019, the depth of the progress of the consistency assessment, the volume procurement led by the National Medical Insurance Bureau was promoted across the country, the basic drug catalog and the medical insurance catalog completed a new round of adjustments, and the key monitoring drug catalog was released.Pressure, gradually the pharmaceutical manufacturing enterprises’ research and development capabilities, cost control capabilities, variety reserves and capital strength have put forward higher requirements.In this year, some enterprises have worked painstakingly in the “pain”, some enterprises have seized the opportunity to transform early, and achieved good results, while some companies have fallen into a “breakthrough” and their performance has been dismal.China Resources Sanjiu, Yixintang’s revenue exceeded 10 billion yuan Among the 18 listed pharmaceutical companies that released their 2019 annual reports, China Resources Sanjiu and Yixintang’s revenue exceeded 10 billion yuan.Among them, China Resources Sanjiu had the highest sales revenue of 147.02 trillion, an annual increase of 9.49%; net profit attributable to shareholders of listed companies is 21.1.2 billion, an annual increase of 47.51%.However, China Resources Sanjiu’s sales expenses are not low, as high as 65.5 billion yuan, accounting for 44% of revenue.55%; R & D expense is 4.4.2 billion US dollars, an annual increase of 24.18%.Regarding performance growth, China Resources Sanjiu said that the company will actively carry out transformation and upgrading in 2019, continue to promote the integration of the innovation system, strengthen brand building, improve operational quality and efficiency, and achieve steady growth in operating performance.Self-diagnosis and treatment business achieved revenue of 75.5.6 billion, an annual increase of 13.36%; prescription drug business achieved operating income of 65.900,000 yuan, an annual increase of 6.36%.In 2019, China Resources Sanjiu sold the equity of its subsidiary Sanjiu Hospital and obtained an investment return of approximately 6.800 million (after tax).Affected by the “Restriction of Resistant Order” and the volume of procurement, in 2019, China Resources Sanjiu’s future operation of Zhongyi Pharmaceutical, a wholly-owned subsidiary mainly producing azithromycin and other generic drugs, will be affected.1.7.2 billion.In addition, the wholly-owned subsidiary Jilin Heshantang’s restricted price of ginseng and the influence of the policy policy of Chinese medicine injection, the company formulated the provision for impairment of goodwill1.9.6 billion yuan.Certain subsidiaries have accrued goodwill impairment provisions3.6.8 billion yuan, which has a certain impact on net profit.The second company with a revenue of 100% is a listed drugstore chain.Reporting intelligence, the company achieved revenue 104.80 ppm, an annual increase of 14.2%; net profit attributable to shareholders of listed companies is 6.4.0 billion, an annual increase of 15.90%.As of December 31, 2019, Yixintang had a total of 6,266 direct-operated chain stores, and 5,221 pharmacies have obtained various types of “medical insurance designated retail pharmacies”, accounting for 83 of the company’s total pharmacies.32%.According to report information, the company’s medical insurance card sales accounted for 41% of the total sales.11%.Yixintang’s company’s performance growth in 2019 is first and foremost, the sales scale of the drug circulation market has steadily increased, and professional services have become the company’s core competitiveness in drug retail.The company’s multi-regional coordinated development, in-depth and comprehensive service improvement, through the scale effect to enhance bargaining power, reduce logistics and control costs, and quickly improve the profitability of the company’s external markets.Along with the release of the annual report, Yixintang also released the 2020 budget stock compensation incentive plan, with 6 million shares to be issued, accounting for 1.% of the issued share capital.06%, the grant price is 10.72 yuan / share, the number of grant targets is 95 people.Southwest Securities analysis believes that Yixintang’s 2019 performance is in line with expectations, and budget incentives replace the basis for stable growth.The subsidiary is out of control, and among the 18 companies in Asia Pacific Pharmaceuticals that have exceeded 2 billion, revenue and net profit have continuously increased by 4 companies, namely Asia Pacific Pharmaceuticals, Lanhai Medical, Shutaishen and Jichuan Pharmaceuticals.The only companies with negative net profit are Asia-Pacific Pharmaceutical and Langhai Medical.Among them, the net profit attributable to the shareholders of listed companies is 1.$ 7.5 billion, at least 253 a year.07 billion.The Asia-Pacific pharmaceutical industry has the worst prospects, with a revenue of 7.09 trillion, an average of 45 years.84%; net profit attributable to shareholders of listed companies is -20.690,000 yuan, an average of 1095 in ten years.57%.In 2019, Shanghai New Peak Biopharmaceutical Co., Ltd. (hereinafter referred to as “Shanghai New Peak”), a subsidiary of Asia-Pacific Pharmaceuticals, lost control and caused major damage.Shanghai Xinfeng is a CRO company acquired by Asia Pacific Pharmaceuticals in December 2015 for US $ 900 million. According to the then purchase agreement, Shanghai Xinfeng should achieve performance commitments and gradually complete restructuring from 2015 to 2018.71%.After the end of the four-year performance commitment period, Shanghai New Peak’s 2019 performance suddenly suffered serious deviations, and the Asia-Pacific Pharmaceutical found that Shanghai Xinshengyuan violated the external guarantee in violation of regulations.In fact, the work of the Asia-Pacific Pharmaceutical Group ‘s entry into Shanghai New Peak was blocked, and Asia-Pacific Pharmaceutical had to declare “Shanghai New Peak Out of Control” on December 25, 2019. Since October 2019, Shanghai New Peak and its subsidiariesNo longer included in the scope of the company’s consolidated statements.Affected by the matter, the China Securities Regulatory Commission investigated the company and Ren Jun, the former actual controller of Shanghai Xinfeng, on the grounds that the company was suspected of information leakage.In the 2019 annual report, Asia-Pacific Pharmaceuticals stated that the company confirmed the investment loss in view of the fact that the company has lost control of Shanghai Xinfeng and its subsidiaries and Shanghai Xinfeng and its subsidiaries cannot resume normal operations.4 billion.For other accounts receivable, construction in progress, fixed assets, development expenditures, and other non-current assets, large amounts of provision for impairment are provided, resulting in significant revenue for the company in 2019.In addition to Shanghai New Peak, Asia-Pacific Pharmaceutical also introduced the transfer of “Biological Products Class 1 New Drug Recombinant Human Keratinocyte Growth Factor-2 (RHKGF-2)” and “Regenerated Human Keratinocyte Growth Factor-2 Drops” to the original Shanghai New PeakItems such as “eye drops” are provided for impairment provision 2.1.8 billion.In addition, the “Wuhan Optics Valley New Drug Research and Development Public Service Platform Construction Project” invested and constructed by the subsidiary Wuhan Optics Valley Asia-Pacific Pharmaceutical Co., Ltd. was terminated, and the provision for impairment of related construction in progress and fixed assets was withdrawn.1.9 billion yuan.The above-mentioned events have led to a significant overlap in the operating performance of Asia Pacific Pharmaceuticals in 2019.Asia-Pacific Pharmaceuticals mentioned in its annual report that due to the impact of the new coronary pneumonia epidemic, the company’s sales in the first quarter are expected to decline, and its net profit is expected to be negative in the first quarter of 2020.Editor Yue Qingxiu proofreading Li Shihui